Allogeneic stem cells transplantation in children, adolescents and young adults previously treated by tisagenlecleucel for B-cell precursor acute lymphoblastic leukemia: a French retrospective SFGM-TC study.

Date publication

octobre 2026

Journal

Transplantation and cellular therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile

Tous les auteurs :
Parreillet M, Vasseur L, Rabian F, Yakouben K, Fahd M, Alani M, Angoso M, Balsat M, Beauvais D, Camus V, Cheikh N, Chevillon F, Contentin N, Garnier N, Dhedin N, Mebarki M, Paillard C, Plantaz D, Pochon C, Rialland F, Guepin GR, Visentin S, Boissel N, Baruchel A, Dalle JH, Dourthe ME

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42926043

Résumé

Tisagenlecleucel have transformed the prognosis of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents and young adults (AYA). However, 50% of patients relapse. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR-T cells should be considered in case of relapse or lack of CAR-T cell persistence.

Référence

Transplant Cell Ther. 2026 10 24;: